Latest news

Celebrating 25 Years of Innovation at BDD

Monument Therapeutics and BDD Launch First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia

Latest blog posts

MCC Propellant Testing. CPHI & PODD conferences.